CNTX
Closed
Context Therapeutics Inc
0.6275
-0.0277 (-4.23%)
Last Update: 01 Jul 2025 23:21:00
Yesterday: 0.6552
Day's Range: 0.625 - 0.6776
Send
sign up or login to leave a comment!
When Written:
0.5622
Context Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative cancer therapies. The company's lead product candidate, CTX-471, is a monoclonal antibody that targets the receptor protein PD-1, which is involved in regulating immune response. CTX-471 is currently in early-stage clinical trials for the treatment of solid tumors.
The company's mission is to develop novel cancer therapies that improve patient outcomes and quality of life. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and was founded in 2017 by a team of experienced biotech executives and scientists.
In addition to CTX-471, Context Therapeutics is also working on developing other cancer therapies, including small molecule inhibitors and other monoclonal antibodies. The company's approach is based on a deep understanding of the molecular pathways involved in cancer growth and progression, and its goal is to develop targeted therapies that can disrupt these pathways and improve patient outcomes.
Context Therapeutics has received funding from a variety of sources, including venture capital firms and government grants. The company is also actively seeking partnerships with other biotech companies and academic institutions to further advance its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's mission is to develop novel cancer therapies that improve patient outcomes and quality of life. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and was founded in 2017 by a team of experienced biotech executives and scientists.
In addition to CTX-471, Context Therapeutics is also working on developing other cancer therapies, including small molecule inhibitors and other monoclonal antibodies. The company's approach is based on a deep understanding of the molecular pathways involved in cancer growth and progression, and its goal is to develop targeted therapies that can disrupt these pathways and improve patient outcomes.
Context Therapeutics has received funding from a variety of sources, including venture capital firms and government grants. The company is also actively seeking partnerships with other biotech companies and academic institutions to further advance its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!